Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease annotation.
Greaves
M
M
Department of Medicine and Therapeutics, University of Aberdeen, and Department of Haematology, Addenbrooke's Hospital, Cambridge, UK. m.geaves@abdn.ac.uk
Baglin
T
T
D017152:Antibodies, Antiphospholipid / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D005165:Factor V / Q000032:analysis / Q000235:genetics; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D019934:International Normalized Ratio; D009154:Mutation; D011237:Predictive Value of Tests; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis; D011516:Prothrombin / Q000032:analysis / Q000235:genetics; D019851:Thrombophilia / Q000175:diagnosis* / Q000235:genetics*; D020246:Venous Thrombosis / Q000175:diagnosis* / Q000188:drug therapy*; D014859:Warfarin / Q000627:therapeutic use
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D015415:Biomarkers; D011486:Protein C; D017293:Protein S; C095381:factor V Leiden; D014859:Warfarin; D005165:Factor V; D011516:Prothrombin; D006493:Heparin